Foster Victor Wealth Advisors LLC Has $9.82 Million Stake in Danaher Co. (NYSE:DHR)

Foster Victor Wealth Advisors LLC grew its position in Danaher Co. (NYSE:DHR) by 50.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,474 shares of the conglomerate’s stock after buying an additional 12,167 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in Danaher were worth $9,820,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tsfg LLC raised its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the 1st quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $51,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 0.4 %

NYSE:DHR opened at $272.68 on Wednesday. The firm’s fifty day moving average is $270.43 and its 200-day moving average is $259.59. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm has a market cap of $201.97 billion, a P/E ratio of 46.22, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the firm posted $2.05 EPS. The company’s quarterly revenue was down 2.9% on a year-over-year basis. Equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity

In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on DHR. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. TD Cowen lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company assumed coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.